Business Context and Reporting Period
This Form 8-K is filed by Salarius Pharmaceuticals, Inc. (not Decoy Therapeutics Inc.) on March 3, 2021. The report details recent capital raising activities, including an At-The-Market (ATM) offering and the commencement of an underwritten public offering.
Key Financial Metrics and Capital Structure
- Cash Position: As of February 28, 2021, the company held $17.4 million in cash and cash equivalents.
- ATM Offering Proceeds: Between February 5, 2021, and the report date, the company sold 2,820,493 shares at an average price of $2.24 per share under an agreement with Ladenburg Thalmann & Co. Inc.
- Warrant Exercises: Between September 30, 2020, and February 28, 2021, the company issued 5,190,508 shares from warrant exercises, generating $4,642,655 in proceeds.
- Outstanding Securities (as of Feb 28, 2021):
- Common Stock: 27,854,867 shares
- Warrants: 7,820,326 (weighted average exercise price: $1.16)
- Options: 1,563,972 (weighted average exercise price: $2.44)
- Revenue and Profit: The filing text does not provide a clear value for revenue, profit, or operating margins.
Material Changes and Recent Events
- Underwritten Offering: On March 3, 2021, the company announced the commencement of an underwritten public offering of its common stock.
- Dilution: Significant share issuance occurred via the ATM program and warrant exercises in the preceding months, increasing the outstanding share count.
Guidance, Outlook, and Risks
The filing does not contain specific financial guidance, forward-looking revenue projections, or detailed management commentary regarding future operational milestones. The primary focus is on the execution of capital raising strategies to fund operations.
Investor Verification Checklist
- Verify the final terms and total proceeds of the underwritten public offering announced on March 3, 2021.
- Confirm the remaining capacity available under the $6.3 million ATM offering agreement.
- Review the company's cash burn rate to assess runway given the $17.4 million cash balance.
- Check for any subsequent filings regarding the pricing of the underwritten offering.